当前位置: X-MOL 学术J. Antimicrob. Chemother. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-09-20 , DOI: 10.1093/jac/dkaa341
Christine Katlama 1, 2 , Lambert Assoumou 2 , Marc-Antoine Valantin 1, 2 , Cathia Soulié 2, 3 , Esteban Martinez 4 , Lydie Béniguel 2 , Olivier Bouchaud 5, 6 , François Raffi 7 , Jean-Michel Molina 8 , Soraya Fellahi 9 , Gilles Peytavin 10 , Anne-Geneviève Marcelin 3 , Sami Kolta 11 , Jacqueline Capeau 9 , Severine Gibowski 12 , Fanny Cardon 12 , Jacques Reynes 13 , Dominique Costagliola 2
Affiliation  

Sir,

中文翻译:

在基于PI的方案中,在45年以上的长期受HIV感染的长期个体中,raltegravir与etravirine联合使用的双重疗法可在96周内维持高水平的病毒抑制:II期ANRS 163 ETRAL研究作者的反应结果。

先生,
更新日期:2020-11-13
down
wechat
bug